

Note: Each trial description lists the treatment stage under the "Stage" heading. Trials that are specifically for GIST are listed first. Trials are then sorted by phase in descending order and then by drug name. See the International trials listed for trials outside the United States.

USA

Imatinib

*Five Year Adjuvant Imatinib
Mesylate (Gleevec®) in
Gastrointestinal Stromal Tumor
(GIST)*

Phase: 2
Stage: Adjuvant
Conditions: Gastrointestinal Stromal
Tumor
Drug Type: KIT/PDGFRA inhibitor
Strategy: Block KIT
NCT #: [NCT00867113](#)
Contact: Novartis
800-340-6843

**Moore's Cancer
Center/UCSD Medical
center**
La Jolla, CA USA
Bethany Parker
858-822-5333
Anthony Reid, MD

**Cedars-Sinai
Outpatient Cancer
Center**
Los Angeles, CA USA
Mimi Lee
310-248-6688
Charles Forscher, MD

University of Colorado
Aurora, CO USA
Tracey McDermott
303-724-2757
Martin McCarter, MD

**Washington Cancer
Institute**
Washington, DC USA
Christina Sheeran
202-877-9386
Dennis Priebat, MD

**Northeast Georgia
Cancer Center
(ACORN)**
Athens, GA USA
Jamie Hodgson
706-353-2990 ext 279
Glen Wiggans, MD

**NE Georgia Health
Systems**
Gainesville, GA USA
Patti Rotunda
770-219-8826
Tim Carey, MD

**Kootenai Cancer
Center**
Coeur d'Alene, ID USA
Robin Gustein
208-666-2293
Brian Samuels, MD

**North Shore University
Health Systems**
Evanston, IL USA
Elita Fine
847-570-2698
Bruce Brockstein, MD

**Dana Farber Cancer
Institute**
Boston, MA USA
Julie Pokela Field
617-632-6708
Chandrajit P. Raut, MD

**Johns Hopkins Sidney
Kimmel Comp Cancer
Center**
Baltimore, MD USA
Margaret Fogel - Ferreira
410-955-7349
Katherine Thornton, MD

Duke University
Durham, NC USA
Wanda Honeycutt
919-668-1861
Richard Riedel, MD

**Dartmouth-Hitchcock
Medical Center**
Lebanon, NH USA
Susan Tarczewski
603-650-6380
Burton Eisenberg, MD

**Southern Nevada
Cancer Research
center**
Las Vegas, NV USA
Jaya Kamath
702-384-0013
Russell Gollard, MD

Montefiore North
Bronx, NY USA
Suzy Graham
718-920-9021
718-920-6821
Stefan Madajewicz, MD

**Queens Cancer Center
of Queens Regional
Hospital**
Jamaica, NY USA
Linda Bulone
718-883-3751
Margaret Kemeny, MD

**Memorial Sloan-
Kettering Cancer
Center**
New York, NY USA
Maria Janakos
212-639-8714
Ron DeMatteo, MD

**Roger Williams Medical
Center**
Providence, RI USA
Robin Davies
401-456-2268
Joseph Espat, MD

**Kingsport Hematolog
Oncology**
Kingsport, TN USA
Teresa Bailey
423-224-3738
Mack Matthews, MD

**MD Anderson Cancer
Center**
Houston, TX USA
Diane Gravel
713-563-6702
Sylvia Abanto
713-794-1919
Jonathan Trent, MD

**South Texas Oncology
Hematology**
San Antonio, TX USA
Pam Sparks
210-593-2651
Ronald Drenkler, MD

**Virginia Oncology
Associates**
Norfolk, VA USA
Wendi Gobhardt
757-466-8683
Michael Lee, MD

Imatinib

Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients

Phase: 3
 Stage: First-line
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: KIT/PDGFR inhibitor
 Strategy: Block KIT
 NCT #: **NCT01031628**
 Contact: Denise Reinke, MS, NP
 734-930-7600
 sarc@sarctrials.org
Sarcoma Oncology Center
 Santa Monica, CA USA
 Viky Chua
 310-552-9999
 vikychoa@aol.com
 Sant Chawla, MD

Masitinib, (AB1010)

Efficacy and Safety of Masitinib (AB1010) in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour

Phase: 3
 Stage: First-line
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: KIT/PDGFR inhibitor
 Strategy: Block KIT
 NCT #: **NCT00812240**
 Contact: Centre Oscar Lambret
 Antoine Adenis, M.D.
 a-adenis@o-lambret.fr
 +33 (0)3 20 29 59 59
MD Anderson - Orlando
 Orlando, FL USA
 Clinical Trials Office - M.D.
 Anderson Cancer Center,
 713-792-3245
 Jon Trent, MD, PhD
Henry Ford Health System
 Detroit, MI USA

Beth Israel Medical Center
 New York, NY USA

Nilotinib or Imatinib

Phase III, Open-Label Study of Nilotinib Versus Imatinib in GIST Patients

Phase: 3
 Stage: First-line
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: KIT/PDGFR inhibitor
 Strategy: Block KIT
 NCT #: **NCT00785785**
 Contact: Novartis Pharmaceuticals
 +1-800-340-6843
Hematology Oncology Services of Arkansas
 Little Rock, AR USA
 Priscilla Gray
 501-320-3217
 Priscilla.Gray@hosaoa.com
 Joanna Tucker
 501 907 6444
 Joanna.Tucker@hosaoa.com
 Brad Baltz, MD
City of Hope
 Duarte, CA USA
 Neeti Arora
 626-256-4673 xt 63019
 narora@coh.org
 Warren Chow, MD
Moores Cancer Center/UCSD Medical center
 La Jolla, CA USA
 Bethany A. Parker
 856-822-5369
 bparker@ucsd.edu
 Tony Reid, MD
City of Hope - Pasadena
 Pasadena, CA USA
 Doni Woo, RN
 626-396-2900
 Mark McNamara, MD
Rocky Mountain Cancer Centers
 Dencer, CO USA
 Silva Mosher
 303-285-5081
 silva.mosher@usoncology.com
 Allen Cohn, MD

Ocala Oncology Center
 Ocala, FL USA
 Patricia Marotta
 352-732-4938
 patricia.marotta@usoncology.com
 Thomas Cartwright, MD

Northeast Georgia Cancer Center (ACORN)
 Athens, GA USA
 Cyndi Pirkle
 706-353-5006
 cpirkle@negacancer.com
 R. Glen Wiggins

Kootenai Cancer Center
 Coeur d'Alene, ID USA
 Robin Gustin
 208 666-2295
 rgustin@kmc.org
 Brian Samuels, MD

University of Pennsylvania
 Philadelphia, PA USA
 Robin Holmes
 215-615-0360
 robin.holmes@uphs.upenn.edu
 Lauren Mennine
 215-349-8913
 lauren.mennine@uphs.upenn.edu
 Weiiina Sun, MD

Pennsylvania Oncology Hematology Associates
 Philadelphia, PA USA
 Susan Kilcoyne
 215-829-6306 ext 138
 susankilcoyne@pennoncology.com
 David Henry, MD

University of Pittsburgh Cancer Institute
 Pittsburgh, PA USA
 Amy Schmotzer
 412-647-6468
 schmotzerar@upmc.edu
 Nathan Bahary, MD

Simmons Cancer Center Univ. of Texas SW Medical Center
 Dallas, TX USA
 Deni von Merveldt
 214 648 5107
 Dendra.vonmerveldt@utsouthwestern.edu

Udit Verma, MD

MD Anderson Cancer Center

Houston, TX USA
Diane Gravel
713-563-6702
dgravel@mdanderson.org
Vu Ta
713-792-2848
Jon Trent, MD, PhD

Tyler Cancer Center

Tyler, TX USA
Linda Dunkin
903-579-9800
linda.dunkin@usonology.com
Donald Richards, MD

Oncology Alliance

Wauwatosa, WI USA
Sara Lam
414-778-4347
slam@oncologyalliance.com
Rachel Davis
414-778-4347
rdavis@oncologyalliance.com
Jonathan S. Maul, MD

BIIB021 (CNF2024)

An Open-Label, 18FDG-PET

Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST) Refractory to, Intolerant of, or Not a Candidate for Imatinib and

Phase: 2
Stage: Gleevec-resistant
Conditions: Gastrointestinal Stromal Tumor
Drug Type: HSP90 inhibitor
Strategy: Destroy KIT
NCT #: **NCT00618319**
Contact: Biogen Idec
oncologyclinicaltrials@biogenidec.com

Mayo Clinic, Rochester
Rochester, MN USA

Memorial Sloan-Kettering Cancer Center

New York, NY USA
Robert Maki, MD

Nilotinib

Nilotinib in Advanced GIST

Phase: 2
Stage: Gleevec-resistant
Conditions: Gastrointestinal Stromal Tumor
Drug Type: KIT/PDGFR inhibitor
Strategy: Block KIT
NCT #: **NCT00782834**
Contact: See site contact info below

Fox Chase Cancer Center

Philadelphia, PA USA
1-888-FOX-CHASE (369-2427)
Margaret von Mehren, M.D.

Regorafenib

Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor

Phase: 2
Stage: Gleevec-resistant
Conditions: Gastrointestinal Stromal Tumor
Drug Type: KIT/PDGFR inhibitor
VEGFR inhibitor (TKI)
Strategy: Block KIT
NCT #: **NCT01068769**
Contact: Suzanne George, MD
617-632-5204
suzanne_george@dfci.harvard.edu

Dana Farber Cancer Institute

Boston, MA USA
Suzanne George, MD

Sorafenib (Nexavar, BAY 43-9006)

Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate

Phase: 2
Stage: Gleevec-resistant
Conditions: Gastrointestinal Stromal Tumor
Drug Type: KIT/PDGFR inhibitor + VEGF inhibitor (TKI) + RAF inhibitor
Strategy: Block KIT + Block KIT Signal Path
NCT #: **NCT00265798**
Contact: Clinical Trials Office - University of Chicago Cancer Research
773-834-7424

University of Chicago

Chicago, IL USA
Clinical Trials Office, 773-834-7424
Hedy Kindler, MD

Sunitinib

*Evaluation of Patients With Bulky
GIST Using Sunitinib*

Phase: 2
 Stage: Gleevec-resistant
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: KIT/PDGFR inhibitor + VEGF inhibitor (antibody)
 Strategy: Block KIT + Block blood vessel growth
 NCT #: **NCT01054911**
 Contact: **UAB Comprehensive Cancer Center**
 Birmingham, AL USA
 Dayle Craig, RN
 205-975-8080
 Dayle.Craig@ccc.uab
 Alma DelGrosso, RN, BSN,
 OCN 205-934-0337
 Alma.DelGrosso@ccc.uab.edu
 James A. Posev. MD

Dasatinib (BMS-354825)

*Trial of Dasatinib in Advanced
Sarcomas*

Phase: 2
 Stage: Gleevec-resistant
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: KIT/PDGFR inhibitor + SRC inhibitor
 Strategy: Block KIT + Block KIT Signal Path
 NCT #: **NCT00464620**
 Contact: Kathleen Granlund
 kegranlund@sarctrials.org
 734-930-7607
Arkansas Children's Hospital
 Little Rock, AR USA
 Bryce Warren
 WarrenBryceA@uams.edu
 Kimo Stine
City of Hope
 Duarte, CA USA
 Neeti Arora
 626-256-4673 ext. 63019
 NArora@coh.org
 Warren Chow, MD

**Cedars-Sinai
Outpatient Cancer
Center**

Los Angeles, CA USA
 Chi Vu
 310-423-2133
 CVu@csocc.com
 Charles Forscher, MD

Stanford Cancer Center

Palo Alto, CA USA
 Maria Ahem
 650-725-6413
 mahem@stanford.edu

Kristen Ganjoo, MD

**Sarcoma Oncology
Center**

Santa Monica, CA USA
 Viky Chua
 (310) 552-9999
 vikychua@aol.com
 Sant Chawla, MD

**Washington Cancer
Institute**

Washington, DC USA
 Christina Sheeran,
 202 877-5371
 christina.m.
 sheeran@medstar.net
 Dennis A. Priebat, MD

**University of Iowa
Hospitals and Clinics**

Iowa City, IA USA
 Melanie Frees, RN
 319-356-1228
 melanie-frees@uiowa.edu
 Mohammed Milhem, MD

**Kootenai Cancer
Center**

Coeur d'Alene, ID USA
 Sheryl Goldon
 208-666-2093
 sgolden@kmc.org
 Brian Samuels, MD

**Oncology Specialists,
Park Ridge**

Park Ridge, IL USA
 Kathy Tolzien
 847-268-8569
 ktolzien@oncmed.net
 Pamela Kaiser, MD

**Indiana University
Simon Cancer Center**

Indianapolis, IN USA
 Kristen Potter, MS
 317-278-6616
 krpotter@iupui.edu
 Daniel Rushing, MD

**Massachusetts General
Hospital**

Boston, MA USA
 Anthony Thomas
 617-643-5411
 athomas2@partners.org
 Edwin Choy, MD

**Johns Hopkins Sidney
Kimmel Comp Cancer
Center**

Baltimore, MD USA
 Adult Oncology, 410-955-8804
 Pediatric Oncology, 410-955-8751
 David Loeb, MD, PhD

University of Michigan

Ann Arbor, MI USA
 Gino Metko
 734-647-8095
 ginom@med.umich.edu
 Scott Schuetze, MD, PhD

**Nebraska Methodist
Hospital**

Omaha, NB USA
 Gladys Pierce
 402-354-5129
 gladys.peirce@nmhs.org
 Kirsten Leu, MD

**Pennsylvania Oncology
Hematology Associates**

Philadelphia, PA USA
 Deb Riordan, RN, BS
 215-829-6712
 debbierrordan@pennoncol
 ogy.com
 Arthur Staddon, MD

**Fox Chase Cancer
Center**

Philadelphia, PA USA
 1-888-FOX-CHASE
 Margeret von Mehren, M.
 D.

**University of
Pittsburgh Cancer
Institute**

Pittsburgh, PA USA
 Lynne Frydrych
 412-623-4036
 frydrychlm2@upmc.edu
 Hussein Tawbi, MD, MSc

**MD Anderson Cancer
Center**

Houston, TX USA
 Joanne Gigstad
 713-563-0510
 jgigstad@mdanderson.org
 Shreyas Patel, MD

Doxorubicin + Flavopiridol

Doxorubicin and Flavopiridol in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery

Phase: 1
 Stage: Gleevec-resistant
 Conditions: Gastrointestinal Stromal Tumor
 Sarcoma
 Drug Type: Transcription inhibitor + Chemotherapy
 Strategy: Freeze the cell division cycle
 NCT #: [NCT00098579](#)
 Contact: See site contact info below
Memorial Sloan-Kettering Cancer Center
 New York, NY USA
 212-639-7573
 dadamod@mskcc.org
 David D'Adamo, MD, PhD,

PLX3397

Safety Study of PLX108-01 in Patients With Solid Tumors

Phase: 1
 Stage: Gleevec-resistant
 Conditions: Solid Tumors
 Drug Type: KIT inhibitor
 Strategy: Block KIT
 NCT #: [NCT01004861](#)
 Contact:
TGen Clinical Research Services
 Scottsdale, AZ USA
 TGen Clinical Research Services
 Cancer Care Coordinator
 877-273-3713
 Daniel D. Hoff, MD
Evergreen Hematology and Oncology
 Spokane, WA USA
 Melanie Matson, RN
 509-464-2873
 Mmatson@evergreen4cure.com
 Stephen P Anthony, DO

SF1126

A Phase I Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study in SF1126, a PI Kinase (PI3K) Inhibitor, Given Twice Weekly by IV Infusion to Patients With Advanced

Phase: 1
 Stage: Gleevec-resistant
 Conditions: Solid Tumors
 Drug Type: PI3K inhibitor
 Strategy: Block KIT Signal Path
 NCT #: [NCT00907205](#)
 Contact: See site contact info below

TGen Clinical Research Services

Scottsdale, AZ USA
 Cathy Costanza, RN, BS, OCN
 480-323-1550
 ccostanza@shc.org
 Jennifer Privratsky
 480-323-1591
 jprivratsky@shc.org
 Ramesh Ramanathan, MD

Arizona Cancer Center

Tucson, AZ USA
 Diane Rensvold, RN
 520-694-9055
 drensvoid@azcc.arizona.edu
 Judy Safarewitz, RN
 520-694-9058
 jsafarewitz@azcc.arizona.edu
 Daruka Mahadevan, MD, PhD

Emory Winship Cancer Institute

Atlanta, GA USA
 Almélida Rene Merrieweather
 404-778-1802
 amerrie@emory.edu
 Donald Harvey, PhD
 404-778-4381
 donald.harvey@emoryhealthcare.org

Indiana University Simon Cancer Center
 Indianapolis, IN USA
 Mary Jane Waddell, RN, CCRC
 317-274-7119
 mjwaddell@iupui.edu
 Jennifer M Funke, MS
 317-278-0328
 jmfunke@iupui.edu
 E. Gabriela Chiorean, MD

AUY922

Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2 + or ER+ Locally Advanced or Metastatic Breast Cancer Patients.

Phase: 1
 Stage: Gleevec-resistant
 Conditions: Solid Tumors
 Drug Type: HSP90 inhibitor
 Strategy: Destroy KIT
 NCT #: [NCT00526045](#)
 Contact: Novartis Pharmaceuticals
 1 800 340-6843

David Geffen School of Medicine at UCLA

Los Angeles, CA USA
 CBritten@mednet.ucla.edu
 310-825-5268
 Carolyn Britten, M.D.

Medical College of Georgia

Augusta, GA USA
 706-721-2505
 tsamuel@mcg.edu
 Thomas Samuel, M.D.

Washington University School of Medicine

St. Louis, MO USA
 800-600-3606
 info@ccadmin.wustl.edu
 Timothy Pluard, MD

Nevada Cancer Institute

Las Vegas, NV USA
 Sandy Lahr
 (702) 822-5174
 Nicholas Vogelzang, MD

MD Anderson Cancer Center

Houston, TX USA
800-392-1611 (in U.S.A.)
713-792-6161 (outside U.S.A.)

Jon Trent, MD, PhD

Cancer Therapy and Research Center

San Antonio, TX USA
210-562-1797
mmita@idd.org
Monica Mita, M.D.

BGT226

A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer

Phase: 1

Stage: Gleevec-resistant

Conditions: Solid Tumors

Drug Type: mTOR inhibitor
PI3K inhibitor

Strategy: Block KIT Signal Path

NCT #: [NCT00600275](#)

Contact: Novartis

800 340-6843

Massachusetts General Hospital

Boston, MA USA
617-726-6225
nisaac1@partners.org
Stephen Isakoff, MD

Nevada Cancer Institute

Las Vegas, NV USA
Dianna Tercan
(702) 822-5483
Lin-Chi Chen, M.D., Ph.D.

Cancer Therapy and Research Center

San Antonio, TX USA
Epp Goodwin
210-450-5798
Francis Giles, MD

GDC-0941 + GDC-0973

A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0973 in Combination With GDC-0941 When Administered Daily in Patients With Locally Advanced or Metastatic Solid

Phase: 1

Stage: Gleevec-resistant

Conditions: Solid Tumors

Drug Type: PI3K inhibitor + MEK inhibitor

Strategy: Block related tumor signal paths

NCT #: [NCT00996892](#)

Contact: Meghan McKenzie
mckenzie.meghan@gene.com

Sarah Cannon Research Institute
Nashville, TN USA

GDC-0980

A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma

Phase: 1

Stage: Gleevec-resistant

Conditions: Solid Tumors

Drug Type: PI3K inhibitor + mTOR inhibitor

Strategy: Block KIT Signal Path

NCT #: [NCT00854152](#)

Contact: Mick O'Quigley
oquigley.michael@gene.com

Dana Farber Cancer Institute

Boston, MA USA
Melissa Hohos
617 632-2201
mhohos@partners.org

Sarah Cannon Research Institute
Nashville, TN USA

GDC-0980

A Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma

Phase: 1

Stage: Gleevec-resistant

Conditions: Solid Tumors

Drug Type: PI3K inhibitor + mTOR inhibitor

Strategy: Block KIT Signal Path

NCT #: [NCT00854126](#)

Contact: Mick O'Quigley
oquigley.michael@gene.com

Dana Farber Cancer Institute

Boston, MA USA
Melissa Hohos
617 632-2201
mhohos@partners.org

SNX-5422

SNX-5422 in Treating Patients With Solid Tumor or Lymphoma That Has Not Responded to Treatment

Phase: 1

Stage: Gleevec-resistant

Conditions: Solid Tumors

Drug Type: HSP90 inhibitor

Strategy: Destroy KIT

NCT #: [NCT00644072](#)

Contact:

Warren Grant Magnuson Clinical Center

Bethesda, MD USA
Clinical Trials Office
888-NCI-1937
Giuseppe Giaccone, MD, PhD

Vorinostat + Bortezomib

*Vorinostat and Bortezomib in
Treating Patients With Metastatic or
Unresectable Solid Tumors*

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: HDAC inhibitor +
Proteasome inhibitor
Strategy: Inhibit protein translation
+ Unblock cell death genes
NCT #: **NCT00227513**
Contact:

**Carbone Cancer
Center, University of
Wisconsin**
Madison, WI USA
Clinical Trials Office
608-262-5223
George Wilding, MD

AMG 479 + AMG 655

*AMG 655 in Combination With AMG
479 in Advanced, Refractory Solid
Tumors*

Phase: 2
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: IGF1R inhibitor + DR5
Inhibitor
Strategy: Block related tumor signal
paths
NCT #: **NCT00819169**
Contact: Amgen Call Center
866-572-6436

**Site name unknown,
Santa Monica 90403**
Santa Monica, CA USA

University of Chicago
Chicago, IL USA
Clinical Trials Office, 773
-834-7424
Hedy Kindler, MD

**Site name unknown,
Indianapolis**
Indianapolis, IN USA

**Site name unknown,
Detroit**
Detroit, MI USA

AT13387

*Phase I Study of HSP90 inhibitor
AT13387 in solid tumors*

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: HSP90 inhibitor
Strategy: Destroy KIT
NCT #: **NCT00878423**
Contact: Andrew Wolanski
617-632-6623
Andrew_Wolanski@dfci.
harvard.edu

**Beth Israel Deaconess
Medical Center**
Boston, MA USA
Sue Gotthardt RN, OCN
(617) 632-9272
Bruce Dezube M.D.

**Massachusetts General
Hospital**
Boston, MA USA
Eunice Kwak, MD

**Dana Farber Cancer
Institute**
Boston, MA USA
Geoffrey Shapiro, MD,
PhD

BAY 73-4506

Phase I study of BAY 73-4506

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: KIT/PDGFR inhibitor
VEGFR inhibitor (TKI)
Strategy: Block KIT
NCT #:
Contact: See site contact info below

**MD Anderson Cancer
Center**
Houston, TX USA
Clinical Trials Office
713-792-3245
Jon Trent, MD, PhD

**South Texas
Accelerated Research
Therapeutics (START)**
San Antonio, TX USA
Tracy Dufresne, RN
210-593-5265
tracy.dufresne@start.stoh.
com

BEZ235

*A Phase I/II Study of BEZ235 in
Patients With Advanced Solid
Malignancies Enriched by Patients
With Advanced Breast Cancer*

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: mTOR inhibitor
PI3K inhibitor
Strategy: Block KIT Signal Path
NCT #: **NCT00620594**
Contact: Novartis
862-778-8300

**Nevada Cancer
Institute**
Las Vegas, NV USA
Dianna Tercan
(702) 822-5483
Wolfram Samlowski, M.D.

**Sarah Cannon
Research Institute**
Nashville, TN USA
615-329-7274
hburris@tnonc.com
Howard A. Burris, III MD

BIIB021 (CNF2024)

Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors

Phase: 1
 Stage: Gleevec-resistant
 Conditions: Solid Tumors
 Drug Type: HSP90 inhibitor
 Strategy: Destroy KIT
 NCT #: **NCT00618735**
 Contact: Biogen Idec
 oncologyclinicaltrials@biogenidec.com
Premier Oncology, Santa Monica
 Santa Monica, CA USA

South Texas Accelerated Research Therapeutics (START)
 San Antonio, TX USA

BIIB022

Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors

Phase: 1
 Stage: Gleevec-resistant
 Conditions: Solid Tumors
 Drug Type: IGF1R inhibitor
 Strategy: Block related tumor signal paths
 NCT #: **NCT00555724**
 Contact: Biogen Idec
 oncologyclinicaltrials@biogenidec.com
Site name unknown, Los Angeles, CA
 Los Angeles, CA USA

University of Colorado
 Aurora, CO USA
 Sarah Eppers
 720-848-0052
 SARA.H.
 EPPERS@ucdenver.edu
 Stephen Leong

Fox Chase Cancer Center

Philadelphia, PA USA
 Kathleen Lear, RN, OCN,
 CCRP Phone: 215-214-1511
 Email: kathleen.lear@fcc.edu
 Roger Cohen, MD

BIIB028

Phase: 1
 Stage: Gleevec-resistant
 Conditions: Solid Tumors
 Drug Type: HSP90 inhibitor
 Strategy: Destroy KIT
 NCT #: **NCT00725933**
 Contact: Biogen Idec
 oncologyclinicaltrials@biogenidec.com

San Deigo Pacific Oncology and Hematology Associates

Encinitas, CA USA
 Karen Brady, RN MSN
 760-752-3340
 kbrady@premiereoncology.com
 Richard Just, M.D.

Site name unknown, Los Angeles, CA
 Los Angeles, CA USA

MD Anderson Cancer Center

Houston, TX USA
 Clinical Trials Office - M.D.
 Anderson Cancer Center,
 713-792-3245
 Jon Trent, MD, PhD

BKM120

A Phase IA, Multi-Center, Open-Label, Dose-Escalation Study of BKM120, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients with Advanced Solid Malignancies

Phase: 1
 Stage: Gleevec-resistant
 Conditions: Solid Tumors
 Drug Type: PI3K inhibitor
 Strategy: Block KIT Signal Path
 NCT #:
 Contact: See site contact info below

Sarah Cannon Research Institute
 Nashville, TN USA
 615-329-SCRI (7274)

GDC-0941

A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable

Phase: 1
 Stage: Gleevec-resistant
 Conditions: Solid Tumors
 Drug Type: PI3K inhibitor
 Strategy: Block KIT Signal Path
 NCT #: **NCT00876109**
 Contact: See site contact info below

TGen Clinical Research Services

Scottsdale, AZ USA
 Lynne Hull
 480-323-1071
 LHull@SHC.org
 Daniel D. Hoff, MD

Dana Farber Cancer Institute

Boston, MA USA
 Melissa Hohos
 617 632-2201
 mhohos@partners.org
 George Demetri, MD, PhD

Karmanos Cancer Institute
 Detroit, MI USA
 Jie Zhang
 313-576-9365
 zhangj@karmanos.org

IMC-A12 + CCI-779

Cixutumumab and Temsirolimus in Treating Young Patients With Solid Tumors That Have Recurred or Not Responded to Treatment

Phase: 1
 Stage: Gleevec-resistant
 Conditions: Solid Tumors
 Drug Type: IGF1R inhibitor + mTOR Inhibitor
 Strategy: Block related tumor signal paths
 NCT #: **NCT00880282**
 Contact:

Children's Hospital of Orange County
 Orange, CA USA
 Violet Shen
 714-532-8636

Children's National Medical Center
 Washington, DC USA
 Clinical Trials Office
 202-884-2549

Masonic Cancer Center at University of Minnesota
 Minneapolis, MN USA
 Clinical Trials Office
 612-624-2620

Cincinnati Children's Hospital Medical Center
 Cincinnati, OH USA
 Clinical Trials Office
 513-636-2799

IMC-A12 + CCI-779

IMC-A12 in Combination With Temsirolimus (CCI-779) in Patients With Advanced Cancers

Phase: 1
 Stage: Gleevec-resistant
 Conditions: Solid Tumors
 Drug Type: IGF1R inhibitor + mTOR Inhibitor
 Strategy: Block related tumor signal paths
 NCT #: **NCT00678769**
 Contact: Aung Naing, MD
 713-563-0181

Karmanos Cancer Institute
 Detroit, MI USA
 all (800) KARMANOS (1-800-527-6266) or e-mail
 info@karmanos.org.

MD Anderson Cancer Center
 Houston, TX USA
 713-563-0181
 Aung Naing, MD

IMC-A12 + CCI-779

Monoclonal Antibody IMC-A12 and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer

Phase: 1
 Stage: Gleevec-resistant
 Conditions: Solid Tumors
 Drug Type: IGF1R inhibitor + mTOR Inhibitor
 Strategy: Block related tumor signal paths
 NCT #: **NCT00678223**
 Contact:

MD Anderson Cancer Center
 Houston, TX USA
 Clinical Trials Office - M.D.
 Anderson Cancer Center,
 713-792-3245
 Aung Naing, MD

IPI-493

A Phase I Dose Escation Study of IPI-493

Phase: 1
 Stage: Gleevec-resistant
 Conditions: Solid Tumors
 Drug Type: HSP90 inhibitor
 Strategy: Destroy KIT
 NCT #: **NCT00724425**
 Contact: See site contact info below

Premier Oncology, Scottsdale
 Scottsdale, AZ USA
 Patricia Shannon, RN
 480 860-5000 xt 223
 pshannon@premiereoncology.com
 David Mendelson, M.D.

San Diego Pacific Oncology and Hematology Associates
 Encinitas, CA USA
 Karen Brady, RN MSN
 760-752-3340
 kbrady@premiereoncology.com
 Richard Just, M.D.

Premier Oncology, Santa Monica
 Santa Monica, CA USA
 Marilyn Mulay, NP
 310-633-8400
 mmulay@premiereoncology.com
 Lee Rosen M.D.

University of Colorado
 Aurora, CO USA
 Stacy Grolnic, RN
 720-848-0655
 stacy.grolnic@uchsc.edu
 Colin Weekes, MD, PhD

Mary Crowley Medical Research Center (Central Office)
 Dallas, TX USA
 Kay Easterwood-Sanchez
 214-658-1943
 Neil Senzer, MD

KW2450

Safety Study to Evaluate KW-2450 in Subjects With Advanced Solid Tumor

Phase: 1
 Stage: Gleevec-resistant
 Conditions: Solid Tumors
 Drug Type: IGF1R inhibitor
 Strategy: Block related tumor signal paths
 NCT #: **NCT00921336**
 Contact: Danyel Davis
 (609) 919-1100
 ddavis@kyowa-kirin-pharma.com
 Niranjana Rao
 (609) 919-1100
 nrao@kyowa-kirin-pharma.com

Memorial Sloan-Kettering Cancer Center
 New York, NY USA

MEDI-573

A Dose-Escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors

Phase: 1
 Stage: Gleevec-resistant
 Conditions: Solid Tumors
 Drug Type: IGF1R inhibitor
 Strategy: Block related tumor signal paths

NCT #: **NCT00816361**
 Contact: Jill Schmidt
 301-398-0000
 schmidtj@medimmune.com
 Lorena DeRienzo
 301-398-0000
 de-rienzol@medimmune.com

Mayo Clinic, Jacksonville
 Jacksonville, FL USA
 Michele Maharaj
 904-953-6136
 maharaj.michele@mayo.edu
 Michael E. Menefee, MD

Karmanos Cancer Institute
 Detroit, MI USA
 Karen Forman
 313-576-8096
 formank@karmanos.org
 Pat LoRusso, DO

Mayo Clinic, Rochester
 Rochester, MN USA
 Janet Lensing
 507-284-3137
 lensing.janet@mayo.edu
 Paul Haluska, MD, PhD

OSI-906

Phase I Study of Continuous OSI-906 Dosing

Phase: 1
 Stage: Gleevec-resistant
 Conditions: Solid Tumors
 Drug Type: IGF1R inhibitor
 Strategy: Block related tumor signal paths
 NCT #: **NCT00514007**
 Contact: OSIP Medical Information
 800.572.1932, x7821
 medical-information@osip.com

Vanderbilt-Ingram Cancer Center
 Nashville, TN USA

OSI-906

Phase I Study of Intermittent OSI-906 Dosing

Phase: 1
 Stage: Gleevec-resistant
 Conditions: Solid Tumors
 Drug Type: IGF1R inhibitor
 Strategy: Block related tumor signal paths
 NCT #: **NCT00514306**
 Contact: OSIP Medical Information
 800.572.1932 ext 7821
 medical-information@osip.com

MD Anderson Cancer Center
 Houston, TX USA
 Edward Kim, MD

PX-478

Phase I Trial of PX-478

Phase: 1
 Stage: Gleevec-resistant
 Conditions: Solid Tumors
 Drug Type: HIF-1a inhibitor
 Strategy: Block related tumor signal paths
 Block tumor blood vessel
 NCT #: [NCT00522652](#)
 Contact: See site contact info below
TGen Clinical Research Services
 Scottsdale, AZ USA
 Lynne Hull
 480-323-1071
 lhull@shc.org
 Daniel D. VonHoff, MD
MD Anderson Cancer Center
 Houston, TX USA
 Hala Abdulkadir
 713-792-9944
 habdulka@mdanderson.org
 Roy S. Herbst, PhD

PX-866

Phase I Trial of Oral PX-866

Phase: 1
 Stage: Gleevec-resistant
 Conditions: Solid Tumors
 Drug Type: PI3K inhibitor
 Strategy: Block KIT Signal Path
 NCT #: [NCT00726583](#)
 Contact: See site contact info below
University of Colorado
 Aurora, CO USA
 Sharon hecker
 720-848-0667
 sharon.hecker@ucdenver.edu
 Antonio Jimeno, MD
MD Anderson Cancer Center
 Houston, TX USA
 Rhonda Clement
 713-563-3559
 rclement@mdanderson.org
 Roy Herbst, MD

R1507

A Multiple Ascending Dose Study of R1507 in Children and Adolescents With Advanced Solid Tumors

Phase: 1
 Stage: Gleevec-resistant
 Conditions: Solid Tumors
 Drug Type: IGF1R inhibitor
 Strategy: Block related tumor signal paths
 NCT #: [NCT00560144](#)
 Contact: Hoffmann-La Roche
 Please reference Study ID Number: NO21200
 973-235-5000
 800-526-6367 (US only)
Site name unknown, Denver 80218
 Denver, CO USA

Site name unknown, Bethesda 20982
 Bethesda, MD USA

Memorial Sloan-Kettering Cancer Center
 New York, NY USA
 212-639-8267
 Dr. Tanya Trippett

University of Pennsylvania
 Philadelphia, PA USA

MD Anderson Cancer Center
 Houston, TX USA
 800-392-1611 Patients
 800-392-1611 Referring MD
 Cynthia E. Herzog

SNX-5422

Safety and Pharmacology of SNX-5422 Mesylate in Subjects With Refractory Solid Tumor Malignancies

Phase: 1
 Stage: Gleevec-resistant
 Conditions: Solid Tumors
 Drug Type: HSP90 inhibitor
 Strategy: Destroy KIT
 NCT #: [NCT00506805](#)
 Contact: Pfizer Oncology Clinical Trial Information
 1-877-369-9753
 PfizerCancerTrials@emergengmed.com
 Pfizer CT.gov Call Center
 1-800-718-1021

TGen Clinical Research Services
 Scottsdale, AZ USA
 Joyce Ingold RN
 480-323-1339
 jingold@shc.org
 Daniel D. Von Hoff, MD

Sarah Cannon Research Institute
 Nashville, TN USA
 Jessica Gilbert
 615 329-7238
 Howard A. Burris, III MD

SNX-5422

Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas

Phase: 1
 Stage: Gleevec-resistant
 Conditions: Solid Tumors
 Drug Type: HSP90 inhibitor
 Strategy: Destroy KIT
 NCT #: **NCT00647764**
 Contact: Pfizer Oncology Clinical Trial Information Service
 1-877-369-9753
 PfizerCancerTrials@emergimgmed.com
 Pfizer CT.gov Call Center
 1-800-718-1021
Site name unknown, Bethesda 20982
 Bethesda, MD USA

Sorafenib + Vorinostat

Phase I Vorinostat + Sorafenib in Patients With Advanced Solid Tumors

Phase: 1
 Stage: Gleevec-resistant
 Conditions: Solid Tumors
 Drug Type: HDAC inhibitor + KIT/PDGFR inhibitor
 Strategy: Block KIT + Unblock cell death genes + Destroy KIT
 NCT #: **NCT00635791**
 Contact: See site contact info below
University of Colorado
 Aurora, CO USA
 Stacy Grolnic
 720-848-0655
 stacy.grolnic@uchsc.edu
 David Ross Camidge MD

STA-9090

Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors

Phase: 1
 Stage: Gleevec-resistant
 Conditions: Solid Tumors
 Drug Type: HSP90 inhibitor
 Strategy: Destroy KIT
 NCT #: **NCT00687934**
 Contact: See site contact info below

Premier Oncology, Santa Monica
 Santa Monica, CA USA
 310-633-8400
 Lee Rosen, MD

US Oncology - Dayton Oncology & Hematology
 Kettering, OH USA
 robert.raju@usoncology.com
 (937)293-1622
 Robert Raju, MD

STA-9090

Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors

Phase: 1
 Stage: Gleevec-resistant
 Conditions: Solid Tumors
 Drug Type: HSP90 inhibitor
 Strategy: Destroy KIT
 NCT #: **NCT00688116**
 Contact: See site contact info below

Dana Farber Cancer Institute
 Boston, MA USA
 Melissa Hohos, RN,
 617-632-2201
 Geoffrey Shapiro, MD,
 PhD

Massachusetts General Hospital
 Boston, MA USA
 Pilar De La Roche Mur
 617-632-5841

Beth Israel Deaconess Medical Center
 Boston, MA USA
 Pilar De La Roche Mur
 617-632-5841

Karmanos Cancer Institute
 Detroit, MI USA
 Dr. Patricia LoRusso
 313-576-8716

Sunitinib + CP-751,871

Phase I Study of CP-751,871 in Combination With Sunitinib in Patients With Advanced Solid Tumors

Phase: 1
 Stage: Gleevec-resistant
 Conditions: Solid Tumors
 Drug Type: KIT/PDGFR inhibitor + IGF1R inhibitor
 Strategy: Block KIT + Block related tumor signal paths
 NCT #: **NCT00729833**
 Contact: EmergingMed
 (877) 369-9753
 PfizerCancerTrials@emergimgmed.com
 Pfizer CT.gov Call Center
 1-800-718-1021

Premier Oncology, Santa Monica
 Santa Monica, CA USA
 310 633-8400
 Lee Rosen

South Texas Accelerated Research Therapeutics (START)
 San Antonio, TX USA

XL147

Study of the Safety and Pharmacokinetics of XL147 in Adults With Solid Tumors

Phase: 1
 Stage: Gleevec-resistant
 Conditions: Solid Tumors
 Drug Type: PI3K inhibitor
 Strategy: Block KIT Signal Path
 NCT #: **NCT00486135**
 Contact: Exelixis Contact Line
 866-939-4041
Dana Farber Cancer Institute
 Boston, MA USA
 Pilar de la Rocha Mur
 617-632-5841
 pilar_DeLaRochaMur@dfci.harvard.edu
 Geoffrey Shapiro, MD
Mary Crowley Medical Research Center (Baylor)
 Dallas, TX USA
 J.R. Dolan
 214-658-1943
 Gerald Edelman MD, PhD

XL228

Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies

Phase: 1
 Stage: Gleevec-resistant
 Conditions: Solid Tumors
 Drug Type: IGF1R inhibitor
 Strategy: Block related tumor signal paths
 NCT #: **NCT00526838**
 Contact: Exelixis Contact Line
 1-866-939-4041
University of Michigan
 Ann Arbor, MI USA
 Nabeela Iqbal
 734-232-0759
 David Smith, MD
Duke University
 Durham, NC USA
 Sharon Norman
 919-681-5257
 Herb Horowitz, MD

XL765

Study of the Safety and Pharmacokinetics of XL765 in Adults With Solid Tumors

Phase: 1
 Stage: Gleevec-resistant
 Conditions: Solid Tumors
 Drug Type: mTOR inhibitor
 PI3K inhibitor
 Strategy: Block related tumor signal paths
 NCT #: **NCT00485719**
 Contact: Exelixis Contact Line
 866-939-4041
Karmanos Cancer Institute
 Detroit, MI USA
 Theresa Laeder 313
 -576-9386
 Patricia LoRusso, DO
South Texas Accelerated Research Therapeutics (START)
 San Antonio, TX USA
 Gina Mangold, MBA 210
 -413-3594
 gmangold@start.stoh.com
 Kyriakos Papadopoulos,
 MD

Sunitinib + Radiation

Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer

Phase: 2
 Stage: Palliative
 Conditions: Any type of Cancer
 Drug Type: KIT/PDGFR inhibitor
 Strategy: Block KIT
 NCT #: **NCT00463060**
 Contact: See site contact info below
Mount Sinai School of Medicine
 New York, NY USA
 212-241-7503
 johnny.kao@mountsinai.org
 Johnny Kao, MD